<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458276</url>
  </required_header>
  <id_info>
    <org_study_id>AC-051-350</org_study_id>
    <nct_id>NCT00458276</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery</brief_title>
  <official_title>Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability
      (problems related to unstable blood pressure) during and after open heart surgery. Tezosentan
      is an investigational intravenous drug that blocks the endothelin receptors. This clinical
      trial will assess the potential benefit of tezosentan compared with placebo in the treatment
      of patients undergoing open heart surgery with cardiopulmonary bypass (CPB). Treatment time
      is from the start of surgery up to 24 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelin-1 levels are increased during and after cardiac surgery with cardiopulmonary
      bypass (CPB), and are associated with many deleterious consequences, including increased
      pulmonary arterial pressure (PAP), increased pulmonary vascular resistance (PVR), reduced
      myocardial contractility, and ultimately right ventricular failure. Right ventricular failure
      during weaning from CPB increases the risk of mortality and morbidity, especially in patients
      with elevated PAP prior to cardiac surgery. Endothelin receptor antagonists (ERAs) have been
      shown to decrease PVR and pulmonary arterial pressure (PAP), and improve right ventricular
      function in patients with pulmonary arterial hypertension. In animal models, ERAs have been
      shown to decrease the incidence of post-bypass pulmonary hypertensive crises. The primary
      objective of this trial is to demonstrate that tezosentan, a dual ERA, reduces the incidence
      of clinically relevant right ventricular failure in patients with pre-operative pulmonary
      hypertension, due to left heart disease, undergoing CPB.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    6 month vital status report not collected after 28 day follow up analysis indicated no
    difference between placebo &amp; tezosentan
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this trial is to demonstrate that tezosentan, a dual ERA, reduces the incidence of clinically relevant right ventricular failure in patients with pre-operative pulmonary hypertension, due to left heart disease, undergoing CPB.</measure>
    <time_frame>During weaning from CPB</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients w/a major clinical event w/in 28 days after study drug initiation like death/major cardiovascular events/infections that prolong hospital stay or require re-admission/new onset of renal failure requiring renal replacement therapy</measure>
    <time_frame>Within 28 days after study initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to weaning from cardiopulmonary bypass</measure>
    <time_frame>Defined as time from release of cross-clamp to successful weaning from CPB</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from end of CPB to final discharge from Intensive Care Unit (ICU)</measure>
    <time_frame>From end of CPB to final discharge from ICU</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">274</enrollment>
  <condition>Heart Diseases</condition>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tezosentan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tezosentan</intervention_name>
    <description>Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo (i.e., normal saline) for i.v. use.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients â‰¥ 18 years of age

          -  Male or female patients (females of child-bearing potential must have been surgically
             sterilized or use a reliable method of contraception).

          -  Patients undergoing complex* cardiac surgery on CPB and having systolic PAP &gt; 40 mmHg
             or mean PAP &gt; 30 mmHg (*surgery on 2 valves, 1 valve and revascularization, or
             reoperation of a valve)

          -  Patients undergoing cardiac surgery on CPB and having pre-operative pulmonary
             hypertension due to left heart disease with systolic PAP &gt; 60 mmHg

          -  Signed written informed consent

        Exclusion Criteria:

          -  Systolic blood pressure &lt; 100 mmHg

          -  Significant chronic lung disease

          -  Emergency surgery

          -  Pregnant/breast-feeding

          -  Investigational drug use within 28 days prior to randomization

          -  Complex adult congenital heart disease.

          -  Severe concomitant illness limiting life expectancy to &lt; 6 months

          -  Participation in a device study that will affect the outcome of the study

          -  Pre-operative use of balloon pump, inotropes/vasopressors, treatment of pulmonary
             arterial hypertension

          -  Known hypersensitivity to tezosentan or drugs of the same class, or any of their
             excipients

          -  Severe liver impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Denault, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Pearl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Michler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Tsui</last_name>
    <role>Study Chair</role>
    <affiliation>Papworth Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rainald Seitelberger, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>AKH University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea D'Armini, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>San Matteo Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center/Albert Einstein College of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute/St. Luke's Episcopal Hospital/Baylor College</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre-University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quebec Heart Institute/Hopital Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dresden Universitatsklinik/Cardiology Center</name>
      <address>
        <city>Gmbh Dresden</city>
        <state>Dresden</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutches Herzzentrum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum der Chirugie-Zchir-des Universitatsklinikums</name>
      <address>
        <city>Frankfurt</city>
        <zip>Main 60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narayana Hrudayalaya</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizam's Institute of Medical Sciences</name>
      <address>
        <city>Hyderabaad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS San Matteo Hospital, Cardiac Surgery</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera &quot;San Giovanni Battista&quot;, Cardiac Surgery Division</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia, 2nd Dept of Cardiac Surgery</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chirurgii Serca, Naczyn I Transplantologii, Szpital Jana Pawla II</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dedinje Cardiovascular Institute</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Cardiovascular Diseases, Clinic of Heart Surgery</name>
      <address>
        <city>Bratslava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern General Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2007</study_first_submitted>
  <study_first_submitted_qc>April 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2007</study_first_posted>
  <disposition_first_submitted>February 11, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 15, 2010</disposition_first_posted>
  <last_update_submitted>February 11, 2010</last_update_submitted>
  <last_update_submitted_qc>February 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Elisabet Lindberg, MD, International Clinical Leader</name_title>
    <organization>Actelion</organization>
  </responsible_party>
  <keyword>Left sided heart disease</keyword>
  <keyword>Elevated pulmonary arterial pressure</keyword>
  <keyword>Right ventricular failure</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>heart-lung machine</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <keyword>tezosentan</keyword>
  <keyword>Actelion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tezosentan</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

